- Home
- GANX vs INMB Comparison
GANX vs INMB Comparison
Compare GANX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GANX | INMB |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 64.7M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GANX | INMB |
|---|---|---|
| Price | $1.24 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $7.20 | $7.00 |
| AVG Volume (30 Days) | ★ 494.7K | 295.4K |
| Earning Date | 11-11-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.46 | 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $55,180.00 | $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $1.21 | $1.09 |
| 52 Week High | $4.34 | $2.60 |
Technical Indicators
Market Signals| Indicator | GANX | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 23.19 | 27.80 |
| Support Level | N/A | $1.36 |
| Resistance Level | $2.01 | $1.76 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 9.51 | 2.92 |
Price Performance
Historical ComparisonAbout GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.